ELIZABETH SHPALL to Receptor, ErbB-2
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Receptor, ErbB-2.
Connection Strength
0.105
-
High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol. 2009 Mar; 21(2):150-7.
Score: 0.040
-
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res. 2004 Nov 01; 10(21):7136-43.
Score: 0.029
-
Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 2000 May; 18(10):2070-80.
Score: 0.022
-
Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant. 2004 Jun; 10(6):415-25.
Score: 0.007
-
Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res. 2004 Apr 15; 10(8):2609-17.
Score: 0.007